Trial Profile
Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Ruxolitinib (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 03 Dec 2021 Status changed from recruiting to completed.
- 10 Feb 2021 Planned End Date changed from 1 Oct 2020 to 1 Jun 2021.
- 10 Feb 2021 Planned primary completion date changed from 1 Oct 2020 to 1 Jun 2021.